Cellectar Biosciences Financial Results Conference Call Announcement
Cellectar Biosciences, Inc. (NASDAQ: CLRB) is excited to inform stakeholders about an upcoming event focused on their financial performance. The late-stage clinical biopharmaceutical company, renowned for its innovative approach to cancer treatment, will announce its full-year financial results for the period ending December 31, 2024. This significant update is set to take place on March 13, 2025, at 8:30 a.m. Eastern Time.
Conference Call Details
The conference call will provide an opportunity for attendees to gain firsthand insights into the company's financial health and strategic direction. Here are the essential details:
- Date: Thursday, March 13, 2025
- Time: 8:30 a.m. Eastern Time
- Toll-Free Number: 1-800-717-1738
- Conference ID: 25759
Following the call, a replay will be accessible in the Events section of the company’s Investor Relations website.
Overview of Cellectar Biosciences
Established as a leader in the field of clinical biopharmaceuticals, Cellectar Biosciences specializes in the development of groundbreaking drugs aimed at cancer treatment. Their mission involves harnessing their proprietary Phospholipid Drug Conjugate™ (PDC) delivery platform, which shows immense potential in enhancing treatment effectiveness and reducing off-target effects.
Innovative Pipeline of Products
Cellectar’s product pipeline includes promising therapeutics such as:
- iopofosine I-131: A PDC engineered for targeted delivery of iodine-131, a radioisotope.
- CLR 121225: This asset focuses on targeting several solid tumors, notably those with significant unmet medical needs like pancreatic cancer.
- CLR 121125: A program targeting additional solid tumors, including triple-negative breast cancer and lung cancer.
These products demonstrate Cellectar’s commitment to developing effective cancer therapies while minimizing side effects commonly associated with traditional treatments.
Recent Clinical Developments
The progress of iopofosine I-131 is noteworthy, as it has been under examination through Phase 2b trials for relapsed or refractory multiple myeloma and Central Nervous System (CNS) lymphoma. The company has also initiated the CLOVER-2 Phase 1b study aimed at pediatric patients suffering from high-grade gliomas, which could result in obtaining a Pediatric Review Voucher from the FDA following approval.
Furthermore, the FDA has recognized iopofosine I-131 with multiple designations, including six Orphan Drug and four Rare Pediatric Drug designations, as well as two Fast Track Designations for various cancer indications.
Connecting with Cellectar Biosciences
To remain updated on the latest innovations and developments, stakeholders are encouraged to visit Cellectar’s official website or follow the company on their social media platforms such as Twitter, LinkedIn, and Facebook. Engaging with the company through these channels ensures timely insights and announcements.
Frequently Asked Questions
What is Cellectar Biosciences focused on?
Cellectar is primarily focused on the discovery and development of drugs for cancer treatment using their proprietary delivery platform.
When will Cellectar announce its financial results?
The financial results for the full year ending December 31, 2024, will be announced on March 13, 2025.
How can I participate in the conference call?
You can participate by calling the toll-free number, 1-800-717-1738, on the specified date and time.
What innovations are included in Cellectar’s product pipeline?
Cellectar's pipeline includes iopofosine I-131, CLR 121225, and CLR 121125, targeting various solid tumors.
Where can I find more information about Cellectar?
More information can be found on Cellectar's official website and through their social media channels.
